BioCentury | Apr 15, 2013
Clinical News

Sonus regulatory update

...companies - SNUS, Bracco Diagnostics Inc. (Milan, Italy), DuPont Merck Pharmaceutical Co. (Wilmington, Del.) and ImaRx Pharmaceutical Corp....
BioCentury | Oct 11, 1999
Company News

ImaRx Pharma, DuPont deal

...agent in Asia and will pay milestones and royalties to DuPont. (DuPont acquires CombiChem, B3) ImaRx Pharmaceutical Corp....
BioCentury | Sep 20, 1999
Clinical News

Definity perflutren ultrasound contrast agent regulatory update

...Last December, DuPont submitted an NDA to the FDA for Definity, which was developed with ImaRx Pharmaceutical Corp....
BioCentury | May 10, 1999
Company News

ImaRx Pharma, Molecular Biosystems, DuPont, Mallinckrodt diagnostics/imaging news

...and Trademark Office recently upheld the '656 patent in a re-examination (see BioCentury, May 3). ImaRx Pharmaceutical Corp....
BioCentury | May 3, 1999
Clinical News

ImaRx Pharma, DuPont regulatory update

...IMRX's U.S. Patent No. 5,527,521 is still under re-examination by the PTO at MB's request. ImaRx Pharmaceutical Corp....
BioCentury | Mar 15, 1999
Clinical News

Definity Perflutren: Phase II

...of the heart, ultrasound is unable to reach the Definity microbubbles. DuPont licensed Definity from ImaRx Pharmaceutical Corp....
BioCentury | Mar 10, 1999
Company News

ImaRx Pharma other research news

...in cells that are difficult to transfect, the efficiency in increased by 10,000, Unger said. ImaRx Pharmaceutical Corp....
BioCentury | Dec 14, 1998
Clinical News

DuPont Pharmaceuticals Inc. regulatory update

...kidney, liver and cardiac structure and function. DuPont, which developed the product in collaboration with ImaRx Pharmaceutical Corp....
BioCentury | Jul 13, 1998
Clinical News

ImaRx Pharma regulatory update

...ImaRx received U.S. Patent No. 5,770,222 covering targeted drug delivery using lipid-covered gas-containing microspheres. ImaRx Pharmaceutical Corp., Tucson...
BioCentury | Jun 29, 1998
Clinical News

DMP 115 perfluorocarbon: Partner Yamanouchi Pharmaceutical Co. Ltd. began clinical testing

ImaRx Pharmaceutical Corp., Tucson, Ariz. Product: DMP 115 perfluorocarbon ultrasound contrast agent Indication: Cardiologic and radiologic imaging Status: Partner Yamanouchi Pharmaceutical Co. Ltd. began clinical testing in Japan of ImaRx's DMP 115 perfluorocarbon microbubble ultrasound...
Items per page:
1 - 10 of 23
BioCentury | Apr 15, 2013
Clinical News

Sonus regulatory update

...companies - SNUS, Bracco Diagnostics Inc. (Milan, Italy), DuPont Merck Pharmaceutical Co. (Wilmington, Del.) and ImaRx Pharmaceutical Corp....
BioCentury | Oct 11, 1999
Company News

ImaRx Pharma, DuPont deal

...agent in Asia and will pay milestones and royalties to DuPont. (DuPont acquires CombiChem, B3) ImaRx Pharmaceutical Corp....
BioCentury | Sep 20, 1999
Clinical News

Definity perflutren ultrasound contrast agent regulatory update

...Last December, DuPont submitted an NDA to the FDA for Definity, which was developed with ImaRx Pharmaceutical Corp....
BioCentury | May 10, 1999
Company News

ImaRx Pharma, Molecular Biosystems, DuPont, Mallinckrodt diagnostics/imaging news

...and Trademark Office recently upheld the '656 patent in a re-examination (see BioCentury, May 3). ImaRx Pharmaceutical Corp....
BioCentury | May 3, 1999
Clinical News

ImaRx Pharma, DuPont regulatory update

...IMRX's U.S. Patent No. 5,527,521 is still under re-examination by the PTO at MB's request. ImaRx Pharmaceutical Corp....
BioCentury | Mar 15, 1999
Clinical News

Definity Perflutren: Phase II

...of the heart, ultrasound is unable to reach the Definity microbubbles. DuPont licensed Definity from ImaRx Pharmaceutical Corp....
BioCentury | Mar 10, 1999
Company News

ImaRx Pharma other research news

...in cells that are difficult to transfect, the efficiency in increased by 10,000, Unger said. ImaRx Pharmaceutical Corp....
BioCentury | Dec 14, 1998
Clinical News

DuPont Pharmaceuticals Inc. regulatory update

...kidney, liver and cardiac structure and function. DuPont, which developed the product in collaboration with ImaRx Pharmaceutical Corp....
BioCentury | Jul 13, 1998
Clinical News

ImaRx Pharma regulatory update

...ImaRx received U.S. Patent No. 5,770,222 covering targeted drug delivery using lipid-covered gas-containing microspheres. ImaRx Pharmaceutical Corp., Tucson...
BioCentury | Jun 29, 1998
Clinical News

DMP 115 perfluorocarbon: Partner Yamanouchi Pharmaceutical Co. Ltd. began clinical testing

ImaRx Pharmaceutical Corp., Tucson, Ariz. Product: DMP 115 perfluorocarbon ultrasound contrast agent Indication: Cardiologic and radiologic imaging Status: Partner Yamanouchi Pharmaceutical Co. Ltd. began clinical testing in Japan of ImaRx's DMP 115 perfluorocarbon microbubble ultrasound...
Items per page:
1 - 10 of 23